Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019

Recent evidence has emerged concerning delayed cutaneous hypersensitivity reactions after infliximab or adalimumab applications in patients with coronavirus disease 2019 (COVID‐19). A few real‐world studies compared the events, clinical features, and prognosis of infliximab‐ or adalimumab‐related de...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Yin, Xuedong, Yu, Linlin, Cheng, Weiwei, Wang, Ling, Zhao, Bin, Li, Zhiling, Jing, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107992/
https://www.ncbi.nlm.nih.gov/pubmed/36700393
http://dx.doi.org/10.1002/jmv.28518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107992/
https://www.ncbi.nlm.nih.gov/pubmed/36700393
http://dx.doi.org/10.1002/jmv.28518

Ejemplares similares